ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
Portfolio Pulse from
Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against ImmunityBio, Inc. (NASDAQ: IBRX) due to possible false statements by the company's officers and directors. The investigation is related to the company's failed attempt to secure regulatory approval for its bladder cancer treatment, Anktiva, in 2023.
November 19, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ImmunityBio, Inc. is under investigation by Schubert Jonckheer & Kolbe LLP for potential false statements by its officers and directors. This is related to the company's failure to obtain regulatory approval for Anktiva in 2023.
The investigation into potential false statements by ImmunityBio's officers and directors could lead to legal challenges and affect investor confidence. The failure to secure regulatory approval for Anktiva, a key product, adds to the negative sentiment, likely impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100